IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo.
We have characterized a cytokine produced by Th2 cells, designated as IL-25. Infusion of mice with IL-25 induced IL-4, IL-5, and IL-13 gene expression. The induction of these cytokines resulted in Th2-like responses marked by increased serum IgE, IgG(1), and IgA levels, blood eosinophilia, and pathological changes in the lungs and digestive tract that included eosinophilic infiltrates, increased mucus production, and epithelial cell hyperplasia/hypertrophy. In addition, our studies show that IL-25 induces Th2-type cytokine production by accessory cells that are MHC class II(high), CD11c(dull), and lineage(-). These results suggest that IL-25, derived from Th2 T cells, is capable of amplifying allergic type inflammatory responses by its actions on other cell types.
Fort
M M
MM
DNAX Research Institute, Palo Alto, CA 94304, USA.
Cheung
J
J
Yen
D
D
Li
J
J
Zurawski
S M
SM
Lo
S
S
Menon
S
S
Clifford
T
T
Hunte
B
B
Lesley
R
R
Muchamuel
T
T
Hurst
S D
SD
Zurawski
G
G
Leach
M W
MW
Gorman
D M
DM
Rennick
D M
DM
D000595:Amino Acid Sequence; D000818:Animals; D019070:Cell Lineage; D002478:Cells, Cultured; D003001:Cloning, Molecular; D004268:DNA-Binding Proteins / Q000172:deficiency / Q000235:genetics; D004802:Eosinophilia / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D005753:Gastric Mucosa / Q000473:pathology; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects*; D006133:Growth Substances / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D006942:Hypergammaglobulinemia / Q000139:chemically induced*; D006965:Hyperplasia; D006984:Hypertrophy; D016167:Integrin alphaXbeta2 / Q000032:analysis; D018793:Interleukin-13 / Q000096:biosynthesis* / Q000235:genetics; D020381:Interleukin-17; D015847:Interleukin-4 / Q000096:biosynthesis* / Q000235:genetics; D015848:Interleukin-5 / Q000096:biosynthesis* / Q000235:genetics; D007378:Interleukins; D007413:Intestinal Mucosa / Q000473:pathology; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008969:Molecular Sequence Data; D009687:Nuclear Proteins; D011657:Pulmonary Eosinophilia / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis; D019948:Receptors, Interleukin-4 / Q000172:deficiency / Q000235:genetics; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000378:metabolism; D018418:Th2 Cells / Q000737:chemistry / Q000378:metabolism*
D004268:DNA-Binding Proteins; D006133:Growth Substances; D000949:Histocompatibility Antigens Class II; C486701:IL25 protein, human; D016167:Integrin alphaXbeta2; D018793:Interleukin-13; D020381:Interleukin-17; D015848:Interleukin-5; D007378:Interleukins; C442281:Mydgf protein, mouse; D009687:Nuclear Proteins; C499311:RAG2 protein, human; D012333:RNA, Messenger; C499308:Rag2 protein, mouse; D019948:Receptors, Interleukin-4; C064655:V(D)J recombination activating protein 2; D015847:Interleukin-4